Literature DB >> 9893712

Molecular mechanisms of poliovirus persistence: key role of capsid determinants during the establishment phase.

I Pelletier1, G Duncan, N Pavio, F Colbère-Garapin.   

Abstract

As viral persistence is of major medical importance, well-characterized, simple models are needed to improve our understanding of persistent infections. We have chosen to study the molecular mechanisms of viral persistence with the poliovirus (PV), because this picornavirus is one of the best characterized animal viruses, it infects the central nervous system which is a target organ for viral persistence, and it belongs to the Picornaviridae family of viruses, which includes several naturally persisting viruses. We have developed models of PV persistence in neuronal and epidermoid cells, and the present review will focus on the latter one because both lytic and persistent PV strains can be used to study the PV-HEp-2 cell interactions. The viral determinants of persistence have been investigated with this model, and PV determinants have proven to be of crucial importance for the establishment of persistence in HEp-2 cells. Precise determinants of PV persistence have been identified for PV serotypes 1 and 3, in capsid proteins VP1 and VP2. These determinants modify the early steps of the PV cycle, and in particular, the conformational modifications of the capsid following virus adsorption onto its receptor. These results permit us to propose several hypotheses concerning PV persistence and the early steps of the PV cycle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9893712     DOI: 10.1007/s000180050261

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  9 in total

1.  Enteroviruses in chronic fatigue syndrome: "now you see them, now you don't".

Authors:  M C Dalakas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-10       Impact factor: 10.154

2.  Multicentre European study of thalamic stimulation in essential tremor.

Authors:  J P R Dick
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-10       Impact factor: 10.154

3.  Enhanced gene silencing in cells cured of persistent virus infection by RNA interference.

Authors:  Isabelle Pelletier; Aure Saulnier; Cynthia Brisac; Sophie Jegouic; Nicolas Vabret; Frédéric Tangy; Bruno Blondel; Florence Colbère-Garapin
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

4.  Molecular mechanisms of coxsackievirus persistence in chronic inflammatory myopathy: viral RNA persists through formation of a double-stranded complex without associated genomic mutations or evolution.

Authors:  P E Tam; R P Messner
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line.

Authors:  Sandra Pinkert; Karin Klingel; Vanessa Lindig; Andrea Dörner; Heinz Zeichhardt; O Brad Spiller; Henry Fechner
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

6.  Persistence of Coxsackievirus B4 in pancreatic ductal-like cells results in cellular and viral changes.

Authors:  E K Alidjinou; I Engelmann; J Bossu; C Villenet; M Figeac; M-B Romond; F Sané; D Hober
Journal:  Virulence       Date:  2017-01-23       Impact factor: 5.882

7.  Establishment of persistent infection with foot-and-mouth disease virus in BHK-21 cells.

Authors:  Xuan Huang; Yong Li; Hui Fang; Congyi Zheng
Journal:  Virol J       Date:  2011-04-14       Impact factor: 4.099

8.  The Transcriptome of Rhabdomyosarcoma Cells Infected with Cytolytic and Non-Cytolytic Variants of Coxsackievirus B2 Ohio-1.

Authors:  Anna Sävneby; Johannes Luthman; Fabian Nordenskjöld; Björn Andersson; A Michael Lindberg
Journal:  PLoS One       Date:  2016-10-19       Impact factor: 3.240

9.  Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal differential cellular gene expression in response to enterovirus 71 infection.

Authors:  Wai Fook Leong; Vincent T K Chow
Journal:  Cell Microbiol       Date:  2006-04       Impact factor: 3.715

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.